Exclusive Summary

• - Fully off-patent and US-registered mature product, ready for rapid multi-country rollout.
• - Addresses high-burden populations in MDD, SAD, and smoking cessation with strong, persistent demand.
• - FDA-GMP and US registration de-risk quality/BE, especially for the historically sensitive 300 mg XL strength.
• - Once-daily 150/300 mg XL improves adherence and offers favorable weight/sexual side-effect profile vs many SSRIs.
• - >90% price discount vs originator enables tender wins and payer adoption with clear volume upside.